Rx Industry’s Economic Value Should Preclude Price Controls, Novartis Says
Executive Summary
The pharmaceutical industry is of "strategic value" to the U.S. economy and should not be jeopardized by instituting drug price controls, Novartis CEO Daniel Vasella, PhD, told the AARP International Forum on Prescription Drug Pricing Policy June 10 in Washington, D.C
You may also be interested in...
Tidbits From The Fourth Quarter Calls, In Brief
AstraZeneca Prilosec generic erosion: AstraZeneca's Prilosec holds 47% share of total prescriptions following generic omeprazole entry in late 2002, CFO Jon Symonds says on Jan. 30 investor call. "We must, of course, be cautious with only six weeks of data available...but it's clear that the erosion rate is significantly less than that observed with either Prozac or Zestril at a similar stage, seemingly consistent with Kudco's inability to fully supply the market." Schwarz' subsidiary Kudco is distributing generic Prilosec on a limited basis due to supply constraints (1"The Pink Sheet" Dec. 16, 2002, p. 30)....Nexium ramp-up: Nexium total prescription share is over 20%, up more than eight percentage points in 2002. Share of total scripts written by gastrointestinal specialists is more than 27%...
Novartis opens Cambridge research facility
Novartis' $250 mil. investment in a 255,000 sq. ft. research facility in Cambridge, Mass. is part of the continuing trend of increasing R&D investments in the U.S. over Europe, company says. Sen. Edward Kennedy (D-Mass.) and Rep. Michael Capuano (D-Mass.) joined Novartis in a May 6 press conference announcing the opening. Research activities are scheduled to begin in the first quarter of 2003 with 400 employees, with an expansion planned to accommodate 900 scientists...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011